International Journal of Gynecology & Obstetrics
Volume 85, Issue 3 , Pages 301-308 , June 2004

Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis

  • S.H. Jee

      Affiliations

    • Department of Epidemiology and Health Promotion, Graduate School of Health Science and Management, Yonsei University, Seoul, South Korea
    • Corresponding Author InformationCorresponding author. Tel.: +82-2-361-5095; fax: +82-2-365-5118
    • ,
  • S.Y. Won

      Affiliations

    • Department of Epidemiology and Health Promotion, Graduate School of Health Science and Management, Yonsei University, Seoul, South Korea
    • ,
  • J.E. Yun

      Affiliations

    • Department of Epidemiology and Health Promotion, Graduate School of Health Science and Management, Yonsei University, Seoul, South Korea
    • ,
  • J.E. Lee

      Affiliations

    • DNA Link, Inc., Seoul, South Korea
    • ,
  • J.S. Park

      Affiliations

    • Department of Obstetrics and Gynecology, The Catholic University of Korea, Seoul, South Korea
    • ,
  • S.S. Ji

      Affiliations

    • Department of Office Automation, Wonju National College, Wonju, South Korea

Received 19 May 2003 ,Revised 20 August 2003 ,Accepted 27 August 2003.

References 

  1. Dyson N, Howley PM, Munger K, Harlow E. The HPV-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;234:934–937
  2. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus type 16 and 18, E6 protein with p53. Science. 1990;248:934–937
  3. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al.  Role of p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393:229–234
  4. Rosenthal AN, Ryan A, Al-Jehani RM, Storey A, Harwood CA, Jacobs IJ. p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet. 1998;352:871–872
  5. Minaguchi T, Kanamori Y, Matsushima M, Yoshikawa H, Taketani Y, Nakamura Y. No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection. Cancer Res. 1998;58:4585–4586
  6. Hayea VM, Hofstra RM, Buys CH, Hollema H, van der Zee AG. Homozygous arginine-72 in wild type p53 and risk of cervical cancer. Lancet. 1998;352:1756
  7. Lanham S, Chmpbell I, Watt P, Gornall R. p53 polymorphism and risk of cervical cancer. Lancet. 1998;352:1631
  8. Helland A, Langerod A, Johnsen H, Olsen AO, Skovlund E, Borresen-Dale AL. p53 polymorphism and risk of cervical cancer. Nature. 1998;396:530–531
  9. Josefsson AM, Magnusson PKE, Ylitalo N, Quarforth-Tubbin P, Ponten J, Adami HO, et al.  p53 polymorphism and risk of cervical cancer. Nature. 1998;396:531–532
  10. Hildsheim A, Schiffman M, Brinton LA, Fraumeni JF, Herrero R, Bratti MC, et al.  p53 polymorphism and risk of cervical cancer. Nature. 1998;196:532
  11. Bertorelle R, Chieco-Bianchi L, Mistro AD. Papillomavirus and p53 codon 72 polymorphism. Int J Cancer. 1999;82:616–617
  12. Ngan HYS, Liu VWS, Liu SS. Risk of cervical cancer is not increased in Chinese carrying homozygous arginine at codon 72 of p53. Br J Cancer. 1999;80:1828–1829
  13. Sonoda Y, Saigo PE, Boyd J. p53 and genetic susceptibility to cervical cancer. J Natl Cancer Inst. 1999;91:557
  14. Giannoudis A, Graham DA, Herrington S. p53 codon 72Ag/Pro polymorphism is not related to HPV type or lesion grade in low- and high-grade squamous intra-epithelial lesions and invasive squamous carcinoma of the cervix. Int J Cancer. 1999;83:66–69
  15. Wang NM, Tsai C, Yeh K, Chen S, Chang J. p53 codon 72Arg polymorphism is not a risk factor for carcinogenesis in the Chinese. Int J Mol Med. 1999;4:249–252
  16. Zehbe I, Voglino G, Wilander E, Genta F, Tommasino M. Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet. 1999;354:218–219
  17. Szarka K, Veress G, Konya J, Gergley L. Frequency of p53 codon 72 genotypes in human papillomavirus associated squamous intraepithelial lesions and cervical cancer. Anticancer Res. 1999;19:2377–2380
  18. Tachezy R, Mikyskova I, Salakova M, Ranst MV. Correlation between human papillomavirus-associated cervical cancer and p53 codon 72 arginine/proline polymorphism. Hum Genet. 1999;105:564–566
  19. Klaes R, Ridder R, Schaefer U, Benner A, Doeberitz MK. No evidence of p53 allele-specific predisposition in human papillomavirus-associated cervical cancer. J Mol Med. 1999;77:299–302
  20. Yamashita T, Yaginuma Y, Saitoh Y, Kawai K, Kurakane T, Hayashi H, et al.  Codon 72 polymorphism of p53 as a risk factor for patients with human papillomavirus-associated squamous intraepithelial lesions and invasive cancer of the uterine cervix. Carcinogenesis. 1999;20:1733–1736
  21. Kim JW, Lee CG, Park YG, Kim KS, Kim IK, Sohn YW, et al.  Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and CYP2E1. Am Cancer Soc. 2000;88:2082–2091
  22. Dokianakis DN, Spandidos DA. p53 Codon 72 Polymorphism as a risk factor in the development of HPV-associated cervical cancer. Mol Cell Biol Res Commun. 2000;3:111–114
  23. Agorastos T, Lambropoulos AF, Constantinidis TC, Kotsis A, Bontis JN. p53 codon 72 polymorphism and risk of intra-epithelial and invasive cervical neoplasia in Greek women. Eur J Cancer Prevent. 2000;9:113–118
  24. Madeleine MM, Shera K, Schwartz SM, Daling JR, Galloway DA, Wipf GC. The p53 Arg72Pro polymorphism, human papillomavirus, and invasive squamous cell cervical cancer. Cancer Epidemiol Biomarkers. 2000;9:225–227
  25. Tenti P, Spaudo VMR, Zappatore R, Carnevali PML, Ranzani GN. p53 codon 72 polymorphism does not affect the risk of cervical cancer in patients from Northern Italy. Cancer Epidemiol Biomarkers. 2000;9:435–438
  26. Pegoraro R, Moodley J, Naiker S, Lanning P, Rom L. The p53 codon 72 polymorphism in black South African women and the risk of cervical cancer. Br J Obstet Gynecol. 2000;107:1164–1165
  27. Baek WK, Cho JW, Suh SI, Suh MH, Shin DH, Cho CH, et al.  p53 Codon 72 polymorphism and risk of cervical carcinoma in Korean women. J Korean Med Sci. 2000;15:65–67
  28. Makni H, Franco EL, Kaiano J, Villa LL, Labrecque S, Dudley R, et al.  p53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int J Cancer. 2000;87:528–533
  29. Duin MV, Snijders PJF, Vossen MTM, Klaasen E, Voorhorst F, Verheijen RHM, et al.  Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis. J General Virol. 2000;81:317–325
  30. Yang YC, Chang CL, Chen ML. Effect of p53 polymorphism on the susceptibility of cervical cancer. Gynecol Obstet Invest. 2001;51:197–201
  31. Zehbe I, Voglino G, Wilander E, Delius H, Marongiu A, Edler L, et al.  p53 Codon 72 Polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res. 2001;61:608–611
  32. Gustafsson AC, Guo Z, Hu X, Ahmadian A, Brodin B, Nilsson A, et al.  HPV-related cancer susceptibility and p53 codon 72 polymorphism. Acta Derm Venereol. 2001;81:125–129
  33. Rezza G, Giuliani M, Garbuglia AR, Serraino D, Cappiello G, Migliore G, et al.  Lack of association between p53 Codon-72 polymorphism and squamous intraepithelial lesions in women with, or at risk for, human immunodeficiency virus and/or human papillomavirus infections. Cancer Epidemiol Biomarkers. 2001;10:565–566
  34. Klug SJ, Wilmotte R, Santos C, Almonte M, Herrero R, Guerrero I, et al.  TP53 Polymorphism, HPV infection, and risk of cervical cancer. Cancer Epidemiol Biomarkers. 2001;10:1009–1012
  35. Andersson S, Rylander E, Strand A, Sallstrom J, Wilander E, et al.  The significance of p53 codon 72 polymorphism for the development of cervical adenocarcinomas. Br J Cancer. 2001;83:1153–1156
  36. Pegoraro RJ, Rom L, Lanning PA, Moodley M, Naiker S, Moodley J, et al.  P53 codon 72 polymorphism and human papillomavirus type in relation to cervical cancer in South African women. Int J Gynecol Cancer. 2002;12:383–388
  37. Calhoun ES, McGovern RM, Janney CA, Cerhan JR, Iturria SJ, Smith DI, et al.  Host genetics polymorphism analysis in cervical cancer. Clin Chem. 2002;48(8):1218–1224
  38. Bhattacharya P, Duttagupta C, Sengupta S. Proline homozygosity in codon 72 of p53: a risk genotype for human papillomavirus related cervical cancer in Indian woman. Cancer Lett. 2002;188:207–211
  39. Saranath D, Khan Z, Tandle AT, Dedhia TP, Sharma B, Contractor R, et al.  HPV16/18 prevalence in cervical lesions/cancers and p53 genotypes in cervical cancer patients from India. Gynecologic Oncol. 2002;86:157–162
  40. Breiburd F, Ramoz N, Salmon J, Orth G, et al.  HLA control in the progression of human papillomavirus infection. Semin Cancer Biol. 1996;7:359–371
  41. Parker MF, Arroyo GF, Geradts J, Sabichi AL, Park RC, Taylor RR, et al.  Molecular characterization of adenocarcinoma of the cervix. Gynecol Oncol. 1997;64(2):242–251

PII: S0020-7292(03)00440-5

doi: 10.1016/j.ijgo.2003.08.017

International Journal of Gynecology & Obstetrics
Volume 85, Issue 3 , Pages 301-308 , June 2004

Article Tools